Recombinant antibody mixtures: production strategies and cost considerations.
about
Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattleBack to the future: recombinant polyclonal antibody therapeutics.Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?Synergistic Neutralization of Pertussis Toxin by a Bispecific Antibody In Vitro and In VivoComplex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry.Antibodies for treatment of Clostridium difficile infection.Multi-therapeutic potential of autoantibodies induced by immune complexes trapped on follicular dendritic cells.Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeutics.A Synthetic Biology approach for consistent production of plant-made recombinant polyclonal antibodies against snake venom toxins.Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants.Evaluating the efficiency of CHEF and CMV promoter with IRES and Furin/2A linker sequences for monoclonal antibody expression in CHO cells.The emerging therapeutic role of antibody mixtures.malERA: An updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication.Versatile and on-demand biologics co-production in yeast.A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line.Snakebites: costing recombinant antivenoms.Recent Advances in Next Generation Snakebite AntivenomsIntegrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel AntivenomsExpanding the Boundaries of Biotherapeutics with Bispecific Antibodies
P2860
Q28534719-0D2E4B67-9657-46AF-AB20-3543548123FCQ33412776-0A2AFF5C-6908-4D27-A203-13DBA5BB4B02Q36269593-ABAF24B8-33D3-4DD5-A6E7-109D502E88D8Q37396968-03D1FCD8-224B-4752-8AE7-47A545C6CADBQ37593690-5B1F02BC-0583-48B1-BCCA-4D2243463AB7Q38208794-271AF32F-D6B3-4962-B18E-67BD0FC00AADQ38685586-30048FBE-834E-4058-8FDA-EDD445C147CAQ39001735-A861880E-C896-4E46-BCE2-316DD88810ABQ39113055-D56C3E88-AC38-4E79-B876-404F5D8EE6A3Q40201894-B340B5D5-290D-4519-ADB3-C5BA58EA598EQ42375722-1C23A7CB-3F50-409A-8C23-44F3B5FF1FE9Q46026271-42751043-9921-478E-95FB-2393606F98F5Q47134819-876EC5CA-1C1F-40D2-BAF4-47BE6CFAE92CQ47192978-8DDC6D8E-8227-4EEB-83D5-AD0D3BCC61E8Q47709174-0BAEE11A-8CE6-411B-87EC-D215C6689D07Q51425970-BDDE1486-C945-44A1-ABFB-D3E118BF9FCEQ56889475-2D3425AD-EB35-47AA-96BC-26158449C9D9Q58646940-696C3C63-DFEA-413D-A2E8-124C00274C43Q58724935-23C01AD6-0918-4AD6-88C3-392E14F4F895
P2860
Recombinant antibody mixtures: production strategies and cost considerations.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recombinant antibody mixtures: production strategies and cost considerations.
@en
type
label
Recombinant antibody mixtures: production strategies and cost considerations.
@en
prefLabel
Recombinant antibody mixtures: production strategies and cost considerations.
@en
P2093
P1476
Recombinant antibody mixtures: production strategies and cost considerations.
@en
P2093
Anne B Tolstrup
Christian Müller
Henrik Næsted
Søren K Rasmussen
Torben P Frandsen
P304
P356
10.1016/J.ABB.2012.07.001
P407
P577
2012-07-20T00:00:00Z